Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 9.6% - Time to Sell?

Key Points

• The stock fell 9.6% on Friday to $23.18, trading just 24,566 shares—about a 90% decline from its average daily volume—after closing at $25.63 the prior session.
• Analysts are mixed but optimistic overall, with a consensus rating of "Moderate Buy", an average price target of $44.25, and individual ratings including 2 Strong Buy, 3 Buy, 1 Hold and 1 Sell.
• Key company metrics: market cap about $1.49 billion, negative P/E (-2.05), 50‑day/200‑day simple moving averages of $27.00 and $19.49 respectively, and roughly 14.2% institutional ownership with several funds initiating positions in the latest quarter.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report)'s stock price fell 9.6% on Friday . The company traded as low as $23.13 and last traded at $23.18. 24,566 shares changed hands during trading, a decline of 90% from the average session volume of 235,007 shares. The stock had previously closed at $25.63.

Analysts Set New Price Targets

Several brokerages recently commented on DMRA. Lifesci Capital upgraded shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research note on Monday, February 2nd. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, December 29th. Evercore began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday. They set an "outperform" rating and a $46.00 price target for the company. Wall Street Zen raised Damora Therapeutics, Inc. Common Stock from a "sell" rating to a "hold" rating in a research note on Saturday, December 6th. Finally, UBS Group started coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a "buy" rating and a $45.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $44.25.

Damora Therapeutics, Inc. Common Stock Price Performance

The company has a market cap of $1.49 billion, a price-to-earnings ratio of -2.05 and a beta of 1.42. The business's 50-day simple moving average is $27.00 and its 200-day simple moving average is $19.49.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Ikarian Capital LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $6,574,000. Janus Henderson Group PLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $40,000. Boothbay Fund Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $2,204,000. Jain Global LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $2,774,000. Finally, Remedium Capital Partners LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $2,772,000. 14.20% of the stock is currently owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.